UBS Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-107,102
| Closed | -$18.4M | – | 11329 |
|
|
2021
Q3 | $18.4M | Buy |
107,102
+30,818
| +40% | +$4.03M | 0.01% | 1563 |
|
|
2021
Q2 | $9.57M | Sell |
76,284
-9,088
| -11% | -$1.15M | ﹤0.01% | 2077 |
|
|
2021
Q1 | $11.6M | Sell |
85,372
-2,415
| -3% | -$312K | ﹤0.01% | 1827 |
|
|
2020
Q4 | $11.2M | Buy |
87,787
+2,847
| +3% | +$334K | ﹤0.01% | 1760 |
|
|
2020
Q3 | $9.56M | Sell |
84,940
-9,051
| -10% | -$901K | ﹤0.01% | 1672 |
|
|
2020
Q2 | $8.96M | Sell |
93,991
-44,282
| -32% | -$4.27M | ﹤0.01% | 1588 |
|
|
2020
Q1 | $12.4M | Sell |
138,273
-63,486
| -31% | -$4.93M | 0.01% | 1259 |
|
|
2019
Q4 | $10.7M | Sell |
201,759
-34,985
| -15% | -$1.6M | ﹤0.01% | 1898 |
|
|
2019
Q3 | $9.35M | Buy |
236,744
+53,897
| +29% | +$2.34M | ﹤0.01% | 1819 |
|
|
2019
Q2 | $7.51M | Buy |
182,847
+24,374
| +15% | +$1.01M | ﹤0.01% | 1985 |
|
|
2019
Q1 | $7.38M | Sell |
158,473
-108,102
| -41% | -$4.75M | ﹤0.01% | 1906 |
|
|
2018
Q4 | $11.6M | Buy |
266,575
+69,387
| +35% | +$3.47M | 0.01% | 1458 |
|
|
2018
Q3 | $11.3M | Buy |
197,188
+4,775
| +2% | +$235K | ﹤0.01% | 1671 |
|
|
2018
Q2 | $9.34M | Sell |
192,413
-87,470
| -31% | -$3.19M | ﹤0.01% | 1818 |
|
|
2018
Q1 | $10.9M | Buy |
279,883
+121,682
| +77% | +$5.17M | ﹤0.01% | 1606 |
|
|
2017
Q4 | $6.71M | Sell |
158,201
-2,629
| -2% | -$98.6K | ﹤0.01% | 2068 |
|
|
2017
Q3 | $6M | Buy |
160,830
+54,780
| +52% | +$1.9M | ﹤0.01% | 2051 |
|
|
2017
Q2 | $3.22M | Buy |
106,050
+56,927
| +116% | +$1.65M | ﹤0.01% | 2549 |
|
|
2017
Q1 | $1.3M | Sell |
49,123
-7,967
| -14% | -$210K | ﹤0.01% | 3329 |
|
|
2016
Q4 | $1.46M | Buy |
57,090
+20,579
| +56% | +$652K | ﹤0.01% | 3207 |
|
|
2016
Q3 | $1.32M | Sell |
36,511
-5,464
| -13% | -$181K | ﹤0.01% | 3208 |
|
|
2016
Q2 | $1.43M | Buy |
41,975
+4,274
| +11% | +$139K | ﹤0.01% | 3063 |
|
|
2016
Q1 | $995K | Sell |
37,701
-5,528
| -13% | -$161K | ﹤0.01% | 3258 |
|
|
2015
Q4 | $2.11M | Buy |
43,229
+7,212
| +20% | +$260K | ﹤0.01% | 2745 |
|
|
2015
Q3 | $897K | Buy |
36,017
+35,217
| +4,402% | +$1.06M | ﹤0.01% | 3452 |
|
|
2015
Q2 | $25K | Sell |
800
-253
| -24% | -$8.16K | ﹤0.01% | 6677 |
|
|
2015
Q1 | $40K | Buy |
+1,053
| New | +$41.9K | ﹤0.01% | 6266 |
|
UBS Group's XLRN Position: Q4 2021 in Review
UBS Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 107,102 shares — an estimated $18.4M sold.
UBS Group first reported a position in XLRN in Q1 2015 and held it in 27 quarters. The position peaked at $18.4M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- UBS Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- UBS Group sold 107,102 Acceleron Pharma shares in Q4 2021, an estimated $18.4M.
- UBS Group first reported a position in Acceleron Pharma in Q1 2015 and held it in 27 quarters.
- UBS Group's Acceleron Pharma position peaked at $18.4M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on UBS Group's 13F filing for Q4 2021, filed 14 Feb 2022.